Corvus Pharmaceuticals, Inc. (CRVS)
10.90
-0.03
(-0.27%)
USD |
NASDAQ |
Oct 02, 16:00
10.91
+0.01
(+0.09%)
After-Hours: 20:00
Corvus Pharmaceuticals Net Income (Quarterly) : -17.96M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -17.96M |
| March 31, 2026 | -13.69M |
| December 31, 2025 | -12.32M |
| September 30, 2025 | -10.16M |
| June 30, 2025 | -7.998M |
| March 31, 2025 | 15.19M |
| December 31, 2024 | -12.11M |
| September 30, 2024 | -40.22M |
| June 30, 2024 | -4.262M |
| March 31, 2024 | -5.701M |
| December 31, 2023 | -6.653M |
| September 30, 2023 | -6.00M |
| June 30, 2023 | -6.503M |
| March 31, 2023 | -7.873M |
| December 31, 2022 | -9.816M |
| September 30, 2022 | -14.83M |
| June 30, 2022 | -8.363M |
| March 31, 2022 | -8.297M |
| December 31, 2021 | -9.236M |
| September 30, 2021 | -10.67M |
| June 30, 2021 | -11.75M |
| Date | Value |
|---|---|
| March 31, 2021 | -11.58M |
| December 31, 2020 | 27.35M |
| September 30, 2020 | -9.796M |
| June 30, 2020 | -10.61M |
| March 31, 2020 | -12.94M |
| December 31, 2019 | -11.05M |
| September 30, 2019 | -11.00M |
| June 30, 2019 | -12.98M |
| March 31, 2019 | -11.64M |
| December 31, 2018 | -10.51M |
| September 30, 2018 | -10.50M |
| June 30, 2018 | -11.63M |
| March 31, 2018 | -14.30M |
| December 31, 2017 | -11.93M |
| September 30, 2017 | -12.72M |
| June 30, 2017 | -14.98M |
| March 31, 2017 | -16.04M |
| December 31, 2016 | -11.09M |
| September 30, 2016 | -10.30M |
| June 30, 2016 | -8.645M |
| March 31, 2016 | -6.347M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 17.96M |
| EPS Diluted (Quarterly) | -0.1944 |
| Enterprise Value | 702.42M |
| Earnings Yield | -5.67% |
| Normalized Earnings Yield | -5.667 |